The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

作者：Yamamoto T^*; Nakai K; Nariai T; Kumada H; Okumura T; Mizumoto M; Tsuboi K; Zaboronok A; Ishikawa E; Aiyama H; Endo K; Takada T; Yoshida F; Shibata Y; Matsumura A

来源：Applied Radiation and Isotopes, 2011, 69(12): 1817-1818.

DOI：10.1016/j.apradiso.2011.02.013

• Glioma
• X-ray
• Chemotherapy
• Temozolomide
• Radiation

The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m(2)) for the treatment of newly diagnosed GBM. BPA uptake is determined by (18)F-BPA-PET and/or (11)C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.

• 出版日期2011-12